We are excited to announce that leading global medical healthcare and research company, Abbott will be joining our tenant community at Blythe Valley Park. The firm will be based in 10,000 sq ft offices in Elder
Click read more to view the full story:
IM Properties has signed up a leading global medical healthcare and research company, Abbott, to 10,000 sq ft at Blythe Valley Park at junction 4 of the M42.
Abbott, which recently acquired St Jude Medical – a global healthcare company for $25bn, is moving into the Elder building which has undergone an £800,000 refurbishment as part of IM Properties on-going investment at Blythe.
The news follows a spate of high profile prelets and lettings at the business park in the past six months to Prologis, Rybrook Holdings and PFK Cooper Parry.
Harry Goodman, Asset Manager for IM Properties said: “We’re very happy that Abbott have decided to move some of their operations to Blythe Valley Park. Their relocation from Stratford-upon-Avon is a testament to the quality of refurbishment at Elder, and the draw of Blythe Valley Park and its great location in Solihull.
“Since acquiring the business park in 2014, we’ve worked hard to ensure all of the existing buildings meet the high standards of quality, design and specification that IM Properties wishes to be associated with, and Elder is another example of that.
Goodman continues: “Abbott is a leading global operator from a brand new sector for us on Blythe Valley Park. They shall sit perfectly with the Blythe brand and our promotion of health & wellbeing as part of IM Properties commitment to offer high quality working environments which helps to attract and retain top talent in the region.”
IM Properties has a further 44 acres of development land available at Blythe Valley Park for Design and Build options, in addition to 40,000-sq ft of existing Grade A space available to let in One Central Boulevard.
IM Properties, based in Coleshill, is one of the largest privately owned property groups in the UK, with an investment and development portfolio of circa £900 million across the UK, Europe and US.